Communiqués Vivos Therapeutics, Inc.

Actions

VVOS

US92859E2072

Equipement, fournitures et distribution médicale

Temps réel estimé Cboe BZX 16:33:59 20/08/2026			Varia. 5j.	Varia. 1 janv.
0,2760 ^USD	+0,11%		-11,23%	-86,65%

14/08	Transcript : Vivos Therapeutics, Inc., Q2 2026 Earnings Call, Aug 14, 2026
14/08	Vivos Therapeutics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Communiqués

16:25	Vivos Therapeutics Opens New Sleep Testing and Treatment Facility in Nevada to Meet Rapidly Growing Patient Demand for Sleep Apnea Testing and Treatment	AQ
17/08	Vivos Therapeutics Schedules Release of Second Quarter 2026 Financial Results and Conference Call	AQ
14/08	Vivos Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Update	AQ
14/08	Vivos Therapeutics Schedules Release of Second Quarter 2026 Financial Results and Conference Call	AQ
11/08	Vivos Therapeutics Expands Greenway Health Partnership to Deploy AI-Enabled Platform Across All Clinical and Revenue Operations	AQ
05/08	Vivos Therapeutics Announces Issuance of New US Patent Broadening Protection for Its Vivos CARE Oral Medical Device Technology	AQ
30/06	Vivos’ Vida® Appliance Shows Statistically Significant Improvement in Insomnia Severity in 100% of Study Participants	AQ
22/06	Vivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred Equity	AQ
11/06	Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering	AQ
10/06	Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients	AQ
08/06	Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026	AQ
08/06	Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing	AQ
05/06	Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing	AQ
20/05	Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update	AQ
15/04	Vivos Therapeutics Reports Full Year 2025 Financial Results	AQ
15/04	Vivos Therapeutics Schedules Release of Full Year 2025 Financial Results and Conference Call	AQ
07/04	Vivos Therapeutics Completes Private Placement with Existing Private Equity Investor, New Seneca Partners	AQ
26/03	Vivos Therapeutics Reports that Supported Professional Practices Have Achieved 'In-Network' Status Across Multiple Commercial Health Insurers and Medicare in Key Nevada Market	AQ
17/03	Recent Study Confirms Fundamental Correlation Between Severity of Obstructive Sleep Apnea and Oral Anatomy	AQ
05/02	Vivos Therapeutics and SoundHealth Announce Collaboration to Expand Access to SoundHealth’s Groundbreaking FDA-Cleared Allergy and Sleep Technologies	AQ
19/01	Vivos Therapeutics Announces Exercise of Warrants for $4.64 Million Gross Proceeds	AQ
16/01	Vivos Therapeutics Announces Exercise of Warrants for $4.64 Million Gross Proceeds	AQ
16/12	Vivos Therapeutics Announces Grand Opening of Affiliated Sleep Center Near Detroit, Michigan	AQ
15/12	Vivos Therapeutics to Participate in Online Fireside Chat with Water Tower Research on December 16, 2025, at 11 am EST	AQ
19/11	Vivos Therapeutics Reports Significant Revenue Growth During the Third Quarter 2025	AQ